177Lu-PSMA-617 (RLT) delivers targeted radiation, has proven survival benefits in Phase III (e.g., the VISION trial in PSMA-positive mCRPC patients progressing after ARTAs and taxanes reported ~30% ORR and ~46% PSA50 response rates), and has distinct toxicities (hematologic, xerostomia) [56]. This evidence concerns the gene FOLH1 and xerostomia.